Urothelial carcinoma (UC) accounts for about 90% of all bladder or urinary tract cancers. UC becomes harder to treat as it advances, resulting in a 5-year survival rate of only 5% for the metastatic stage (m-UC). Given the poor prognosis for these advanced patients, there was a high need for additional treatment options and until recently, only a few therapeutic options were available. The treatment landscape has dramatically changed in recent years with the introduction of immune checkpoint inhibitors and the development of novel targeted agents.
Checkpoint inhibitor drugs release a natural brake on the immune system. This allows the immune cells to recognize and attack tumors. The drugs work by blocking the interaction of PD-1 on the surface of immune cells with PD-L1, a protein on the surface of cancer cells that keeps the immune system from attacking them.
- atezolizumab (Tecentriq®), avelumab (Bavencio®) and durvalumab (Imfinzi®) are drugs that block PD-L1 to boost the immune system's response against the cancer cells.
- nivolumab (Opdivo®) and pembrolizumab (Keytruda®) block PD-1.
Capitalizing on our unique expertise in the Bladder Cancer market and in patients chart-based research, mUCsyndiTrackTM, our advanced urothelial carcinoma syndicated study uses real-world data to monitor the evolution of m-UC management.
Example of recent release:
- Data available in France, Germany, UK, Spain, Italy
- 353 Oncologists and Urologists
- 2,038 real-world, locally advanced or metastatic urothelial carcinoma (m-UC) patient charts
- Patient shares by line of treatment (incl. platinum-ineligible)
- Treatment schemes for each line of treatment
- Identify dynamics of treatments from 1L to Maintenance and from Maintenance to 2L
- Analysis of patient characteristics
- Measure duration of treatment